See it in your slideRequest a demo
Octo · H&EBuilt on Kraken

Octo Immune

Immune cell detection on H&E

Immune cell detection and density on routine H&E — no extra stain, no extra day.

Request a demoSee the product sheet
Octo Immune output
Octo Immune: raw slide
H&EOcto Immune
Lymphocytes, plasma cells, macrophages and neutrophils mapped on H&E · drag to compare
The problem

Immune infiltrate is scored semi-quantitatively

Tumour-infiltrating lymphocytes are estimated as a percentage of stromal area, semi-quantitatively, and the estimate moves between readers.

Why it matters

Immune density is prognostic

In rectal cancer our immune profiling from H&E predicted chemo-radiotherapy response across a clinical trial and real-world cohorts (eBioMedicine, 2025). A count makes that usable.

The immune landscape

Who is in the tumour, and how many

Each immune cell is classified and counted, so the infiltrate is a composition rather than a grade.

LymphocytesPlasma cellsMyeloid cellsNeutrophils

Illustrative composition. Real proportions come from the slide.

What changes

Three things you stop doing by hand

  1. 01
    Cells, not impressions

    Trained with Immunocto, an automatically generated immune-cell database (Medical Image Analysis, 2024).

  2. 02
    A score that travels

    Density per mm² by compartment, the same on every read.

  3. 03
    The whole tumour bed

    Whole-slide immune map rather than a hotspot impression; tumour and stroma compartments separated.

Outputs

What you get back

Immune cell densitycells per mm², overall and by compartment (tumour / stroma)data
Immune mapevery immune cell marked on the slideoverlay
TIL scorestandardised stromal TIL scoredata
Per-cell exportcoordinates and classCSV / JSON
Reported to standard

TIL assessment following the International Immuno-Oncology Biomarker Working Group method · Reference →

Evidence

Evidence

942
cases in validation
eBioMedicine
immune profiling predicts CRT outcome (2025)
Med. Image Anal.
Immunocto database (2024)
< 2 min
per slide

Immune profiling from H&E predicted chemo-radiotherapy outcome in rectal cancer across trial and real-world cohorts (eBioMedicine, 2025). Regulatory status: research use only.

Also in the Octo family
Octo

Octo Cellularity

Tumour cellularity and tumour–stroma ratio on H&E

Read more →Octo

Octo Mitosis

Mitotic figure detection and hotspot mapping on H&E

Read more →Octo

Octo E-N

Eosinophil and neutrophil counts on H&E

Read more →Octo

Octo Duct

Duct detection and grading in pancreatic adenocarcinoma

Read more →

Try Octo Immune

Run it on a slide in the platform, or ask for the product sheet with the full output specification.

See it in your slideRequest a demo